Where is RBQM Heading in The Future With AI?

Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM) in clinical trials. With experience at both CluePoints and Veeva, Young discusses AI’s role, transparency, and the future of risk management in clinical trials.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Blog

ICH E6(R3), Demystified Part 4: Informed Consent

From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often...

Blog

RBQM for the Mid-Market Explained

Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...

Blog

5 Myths Mid-Market Teams Believe About RBQM and What ICH E6(R3) Actually Requires

Risk-Based Quality Management (RBQM) is no longer a future-state concept. Under ICH E6(R3), it is a...